• 1
    Hepatitis C fact sheet. Available at: Accessed July 13, 2009.
  • 2
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
  • 3
    Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432: 922-924.
  • 4
    Guedj J, Rong L, Dahari H, Perelson AS. A perspective on modelling hepatitis C virus infection. J Viral Hepat 2010; 17: 825-833.
  • 5
    Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky J, et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007; 133: 1132-1143.
  • 6
    Adiwijaya B, Hare B, Caron P, Randle J, Neumann A, Reesink H, et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir Ther 2009; 14: 591-595.
  • 7
    Herrmann E, Zeuzem S, Sarrazin C, Hinrichsen H, Benhamou Y, Manns M, et al. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor, BILN 2061. Antivir Ther 2006; 11: 371-376.
  • 8
    Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van't Klooster G, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138: 913-921.
  • 9
    Morcos P, Kulkarni R, Ipe D, Tran J, Bradford W, Seiwert S, et al. Pharmacokinetics/pharmacodynamics (PK/PD) of combination RG7227 and RG7128 therapy from INFORM-1 demonstrates similar early HCV viral dynamics when RG7227 is combined with either Peg-IFN/ribavirin (SoC) or RG7128 [Abstract]. HEPATOLOGY 2009; 50: 1041A.
  • 10
    Reesink H, Zeuzem S, Weegink C, Forestier N, van Vliet A, van de Wetering de Rooij J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997-1002.
  • 11
    Forestier N, Reesink H, Weegink C, McNair L, Kieffer T, Chu H, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. HEPATOLOGY 2007; 46: 640-648.
  • 12
    Shudo E, Ribeiro RM, Talal AH, Perelson AS. A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther 2008; 13: 919-926.
  • 13
    Chu H, Herrmann E, Reesink H, Forestier N, Weegink C, McNair L, et al. Pharmacokinetics of VX-950, and its effect on hepatitis C viral dynamics [Abstract]. HEPATOLOGY 2005; 42: 694A.
  • 14
    Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 2005; 49: 1020-1038.
  • 15
    Pinheiro J, Bates D. Mixed-Effects Models in S and S-PLUS. New York, NY: Springer Verlag; 2000.
  • 16
    Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. HEPATOLOGY 2007; 46: 631-639.
  • 17
    Adiwijaya BS, Herrmann E, Hare B, Kieffer T, Lin C, Kwong AD, et al. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol 2010; 6: 1-13.
  • 18
    Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. HEPATOLOGY 2003; 37: 1343-1350.
  • 19
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  • 20
    Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2: 30-32.
  • 21
    Takahashi K, Asabe S, Wieland S, Garaigorta U, Gastaminza P, Isogawa M, et al. Plasmacytoid dendritic cells sense hepatitis C virus–infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci U S A 2010; 107: 7431.
  • 22
    Dahari H, Sainz B Jr, Perelson AS, Uprichard SL. Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. J Virol 2009; 83: 6383-6390.
  • 23
    Guedj J, Neumann AU. Understanding hepatitis C viral dynamics with direct-acting antiviral agens due to the interplay between intracellular replication and cellular infection dynamics. J Theor Biol 2010; 267: 330-340.
  • 24
    Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006; 23: 1043-1054.
  • 25
    Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
  • 26
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
  • 27
    Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462.
  • 28
    Lok A, Gardiner D, Lawitz E. Combination therapy with BMS-790052 and BMS-650032 alone or with pegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders [Abstract]. HEPATOLOGY 2010; 52: 877A.
  • 29
    Zeuzem S, Buggisch P, Agarwal K, Manns M, Marcellin P, Foster G, Sereni D, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naïve, genotype 1 HCV subjects [Abstract]. HEPATOLOGY 2010; 52: 877A.
  • 30
    Zeuzem S, Asselah T, Angus PW, Zarski JP, Larrey D, Müllhaupt B, et al. Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C [Abstract]. HEPATOLOGY 2010; 52: 877A.
  • 31
    Gane E, Roberts S, Stedman C, Angus P, Ritchie B, Elston R, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.
  • 32
    Vertex provides update to ongoing phase 2 study evaluating combinations of telaprevir and VX-222 for the treatment of hepatitis C [press release]. Cambridge, MA: Vertex Pharmaceuticals. Available at: